Home | All intervention

[RDF data]
Intervention #100402 (Drug:Olmesartan medoxomil-hydrochlorothiazide)

Resource URI: http://static.linkedct.org/resource/intervention/100402
PropertyValue
linkedct:description Subjects in North America and South Africa: Olmesartan 20 mg and medoxomil-hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For subjects who do not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan 40 mg and medoxomil-hydrochlorothiazide 25 mg. Subjects in Europe: Olmesartan 20 mg and medoxomil-hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For subjects who do not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan 20 mg and medoxomil-hydrochlorothiazide 25 mg.
is linkedct:intervention of <http://static.linkedct.org/resource/trials/NCT00996281>
linkedct:intervention_id 100402 (xsd:int)
linkedct:intervention_name Olmesartan medoxomil-hydrochlorothiazide
linkedct:intervention_type Drug
rdfs:label Intervention #100402 (Drug:Olmesartan medoxomil-hydrochlorothiazide)
rdf:type linkedct:intervention